{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:14:52Z","timestamp":1783473292499,"version":"3.55.0"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Continuation of oral anticoagulation (OAC) after successful atrial fibrillation (AF) ablation remains debated. With recent randomized controlled trials addressing this question, an updated meta-analysis is needed to inform clinical decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A comprehensive search of PubMed\/MEDLINE, Embase, Web of Science, and Scopus was performed through 24 November 2025, to identify studies comparing clinical outcomes in patients who continued vs. discontinued OAC after AF catheter ablation. Overall, continuing OAC was not significantly associated with the risk of stroke\/TIA (OR: 1.48, 95% CI: 0.84\u20132.60; P = 0.16). However, when stratified by CHA2DS2-VASc score, patients with scores \u22652 had a significantly lower risk of stroke\/TIA with OAC continuation (OR: 0.42, 95% CI: 0.18\u20130.95; P = 0.04). This protective effect was further supported in studies with well-balanced baseline risk between groups, where OAC continuation was associated with a significantly lower risk of stroke\/TIA (OR: 0.50, 95% CI: 0.34\u20130.72; P &amp;lt; 0.01). Conversely, OAC continuation significantly increased the risk of major bleeding. No significant association was observed for major adverse cardiac events or all-cause mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with CHA2DS2-VASc scores \u22652, particularly when baseline risk is well-balanced between groups, continuation of OAC after AF ablation is associated with a significantly lower risk of stroke\/TIA. These findings support continuing OAC in higher-risk patients (CHA2DS2-VASc \u22652). However, given the significantly increased risk of major bleeding associated with OAC continuation, the decision to continue anticoagulation in lower-risk patients requires careful consideration, as no clear thromboembolic benefit was observed in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/europace\/euag104","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:30:11Z","timestamp":1783470611000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes of continuing vs. discontinuing oral anticoagulation after atrial fibrillation ablation: an updated systematic review and meta-analysis of observational studies and randomized controlled trials"],"prefix":"10.1093","volume":"28","author":[{"given":"Sandeep Samethadka","family":"Nayak","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Yale New Heaven Health Bridgeport Hospital , 267 Grant St, Bridgeport, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4985-2899","authenticated-orcid":false,"given":"Ehsan","family":"Amini-Salehi","sequence":"additional","affiliation":[{"name":"School of Medicine, Guilan University of Medical Sciences , Rasht ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7980-8720","authenticated-orcid":false,"given":"Negin","family":"Letafatkar","sequence":"additional","affiliation":[{"name":"School of Medicine, Guilan University of Medical Sciences , Rasht ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7610-9314","authenticated-orcid":false,"given":"Arash","family":"Arya","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Halle University Hospital , Halle (Saale) ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9902-2313","authenticated-orcid":false,"given":"Shahriar","family":"Ghodous","sequence":"additional","affiliation":[{"name":"School of Medicine, Guilan University of Medical Sciences , Rasht ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4875-6133","authenticated-orcid":false,"given":"Maryam","family":"Jafari","sequence":"additional","affiliation":[{"name":"School of Medicine, Guilan University of Medical Sciences , Rasht ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6328-8468","authenticated-orcid":false,"given":"Amir","family":"Nasrollahizadeh","sequence":"additional","affiliation":[{"name":"Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4225-2986","authenticated-orcid":false,"given":"Anoop","family":"Gurram","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Department of Hospital Medicine, , Cleveland, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2762-4211","authenticated-orcid":false,"given":"Javad","family":"Nadali","sequence":"additional","affiliation":[{"name":"Nursing Research Center, Golestan University of Medical Sciences , Gorgan ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8554-8400","authenticated-orcid":false,"given":"Seyedeh Mohadese","family":"Mosavi Mirkalaie","sequence":"additional","affiliation":[{"name":"School of Medicine, Guilan University of Medical Sciences , Rasht ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0940-3927","authenticated-orcid":false,"given":"Anya","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale New Heaven Health Bridgeport Hospital , 267 Grant St, Bridgeport, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7634-370X","authenticated-orcid":false,"given":"Payam","family":"Kabiri","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Epidemiology, School of Public Health, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1653-9232","authenticated-orcid":false,"given":"Darshan Madhav","family":"Sonde","sequence":"additional","affiliation":[{"name":"Industrious, University Ave Hey Noah AI Inc, , Palo Alto, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8244-2054","authenticated-orcid":false,"given":"Bita","family":"Amirian","sequence":"additional","affiliation":[{"name":"School of Medicine, Guilan University of Medical Sciences , Rasht ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0740-6399","authenticated-orcid":false,"given":"Ali","family":"Bozorgi","sequence":"additional","affiliation":[{"name":"Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"2026070720300632200_euag104-B1","article-title":"Atrial fibrillation: epidemiology, screening and digital health","volume":"37","author":"Linz","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2026070720300632200_euag104-B2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/jce.15759","article-title":"Atrial fibrillation: epidemiology, pathophysiology, and clinical complications (literature review)","volume":"34","author":"Bizhanov","year":"2023","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026070720300632200_euag104-B3","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41569-022-00820-8","article-title":"Epidemiology and modifiable risk factors for atrial fibrillation","volume":"20","author":"Elliott","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"2026070720300632200_euag104-B4","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euaf027","article-title":"Global, regional, and national burden of atrial fibrillation and atrial flutter from 1990 to 2021: sex differences and global burden projections to 2046-a systematic analysis of the Global Burden of Disease Study 2021","volume":"27","author":"Tan","year":"2025","journal-title":"Europace"},{"key":"2026070720300632200_euag104-B5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/heartjnl-2019-314898","article-title":"Stroke and thromboembolism prevention in atrial fibrillation","volume":"106","author":"Jame","year":"2020","journal-title":"Heart"},{"key":"2026070720300632200_euag104-B6","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030380","article-title":"Efficacy and safety of direct oral anticoagulants for stroke prevention in older patients with atrial fibrillation: a network meta-analysis of randomized controlled trials","volume":"12","author":"Lin","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026070720300632200_euag104-B7","article-title":"Comparison of outcomes of direct oral anticoagulants versus vitamin K antagonists for atrial fibrillation and chronic kidney disease: a systematic review and meta-analysis","volume":"27","author":"Luo","year":"2025","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"2026070720300632200_euag104-B8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41569-020-00451-x","article-title":"Catheter ablation for atrial fibrillation: current indications and evolving technologies","volume":"18","author":"Parameswaran","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"2026070720300632200_euag104-B9","doi-asserted-by":"crossref","first-page":"E105","DOI":"10.1093\/eurheartj\/suaa072","article-title":"Subclinical atrial fibrillation: when to give NAO?","volume":"22","author":"Patti","year":"2020","journal-title":"Eur Heart J Suppl"},{"key":"2026070720300632200_euag104-B10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.amjcard.2019.04.027","article-title":"Thromboembolism in the absence of atrial fibrillation","volume":"124","author":"Smietana","year":"2019","journal-title":"Am J Cardiol"},{"key":"2026070720300632200_euag104-B11","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"2026070720300632200_euag104-B12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.1320","article-title":"Discontinuation of oral anticoagulation after successful atrial fibrillation ablation","volume":"8","author":"Iwawaki","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026070720300632200_euag104-B13","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/eurheartj\/ehad798","article-title":"Oral anticoagulation after atrial fibrillation catheter ablation: benefits and risks","volume":"45","author":"Kanaoka","year":"2024","journal-title":"Eur Heart J"},{"key":"2026070720300632200_euag104-B14","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/jama.2025.14679","article-title":"Long-term anticoagulation discontinuation after catheter ablation for atrial fibrillation: the ALONE-AF randomized clinical trial","volume":"334","author":"Kim","year":"2025","journal-title":"JAMA"},{"key":"2026070720300632200_euag104-B15","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/jce.13476","article-title":"Anticoagulation use and clinical outcomes after catheter ablation in patients with persistent and longstanding persistent atrial fibrillation","volume":"29","author":"Liang","year":"2018","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026070720300632200_euag104-B16","article-title":"Discontinuation of oral anticoagulation therapy after successful atrial fibrillation ablation: a systematic review and meta-analysis of prospective studies","volume":"16","author":"Liu","year":"2021","journal-title":"PLoS One"},{"key":"2026070720300632200_euag104-B17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/jce.13822","article-title":"Anticoagulation after catheter ablation of atrial fibrillation: an unnecessary evil? A systematic review and meta-analysis","volume":"30","author":"Proietti","year":"2019","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026070720300632200_euag104-B18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa2509688","article-title":"Antithrombotic therapy after successful catheter ablation for atrial fibrillation","volume":"394","author":"Verma","year":"2026","journal-title":"N Engl J Med"},{"key":"2026070720300632200_euag104-B19","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026070720300632200_euag104-B20","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/europace\/eut406","article-title":"Incidence of cerebral thromboembolic events during long-term follow-up in patients treated with transcatheter ablation for atrial fibrillation","volume":"16","author":"Gaita","year":"2014","journal-title":"Europace"},{"key":"2026070720300632200_euag104-B21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1540-8167.2011.02141.x","article-title":"Anticoagulant therapy and risk of cerebrovascular events after catheter ablation of atrial fibrillation in the elderly","volume":"23","author":"Guiot","year":"2012","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026070720300632200_euag104-B22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijcard.2020.08.005","article-title":"Long-term incidence and predictive factors of thromboembolic events after a cryoballoon ablation for atrial fibrillation","volume":"321","author":"Hermida","year":"2020","journal-title":"Int J Cardiol"},{"key":"2026070720300632200_euag104-B23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/heartjnl-2011-300720","article-title":"Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death","volume":"98","author":"Hunter","year":"2012","journal-title":"Heart"},{"key":"2026070720300632200_euag104-B24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1161\/CIRCEP.111.962100","article-title":"Natural history and long-term outcomes of ablated atrial fibrillation","volume":"4","author":"Hussein","year":"2011","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2026070720300632200_euag104-B25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/jce.13138","article-title":"Risk of stroke and recurrence after AF ablation in patients with an initial event-free period of 12 months","volume":"28","author":"Kochh\u00e4user","year":"2017","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026070720300632200_euag104-B26","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jacc.2007.10.044","article-title":"Clinical outcomes of catheter substrate ablation for high-risk patients with atrial fibrillation","volume":"51","author":"Nademanee","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026070720300632200_euag104-B27","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1253\/circj.CJ-19-0602","article-title":"Current status and clinical outcomes of oral anticoagulant discontinuation after ablation for atrial fibrillation in Japan\u2015findings from the AF Frontier Ablation Registry \u2015","volume":"83","author":"Okumura","year":"2019","journal-title":"Circ J"},{"key":"2026070720300632200_euag104-B28","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/CIRCULATIONAHA.106.641225","article-title":"Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation","volume":"114","author":"Oral","year":"2006","journal-title":"Circulation"},{"key":"2026070720300632200_euag104-B29","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1161\/CIRCEP.111.963231","article-title":"Very low risk of thromboembolic events in patients undergoing successful catheter ablation of atrial fibrillation with a CHADS2 score \u22643 a long-term outcome study","volume":"4","author":"Saad","year":"2011","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2026070720300632200_euag104-B30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jacc.2009.11.039","article-title":"The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation","volume":"55","author":"Themistoclakis","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026070720300632200_euag104-B31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10840-013-9835-1","article-title":"Discontinuing anticoagulation following successful atrial fibrillation ablation in patients with prior strokes","volume":"38","author":"Winkle","year":"2013","journal-title":"J Interv Card Electrophysiol"},{"key":"2026070720300632200_euag104-B32","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1253\/circj.CJ-11-0065","article-title":"Incidence of late thromboembolic events after catheter ablation of atrial fibrillation","volume":"75","author":"Yagishita","year":"2011","journal-title":"Circ J"},{"key":"2026070720300632200_euag104-B33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/europace\/euz235","article-title":"The safety of discontinuation of oral anticoagulation therapy after apparently successful atrial fibrillation ablation: a report from the Chinese Atrial Fibrillation Registry study","volume":"22","author":"Yang","year":"2020","journal-title":"Europace"},{"key":"2026070720300632200_euag104-B34","doi-asserted-by":"crossref","first-page":"940","DOI":"10.21037\/apm-20-565","article-title":"Real-world investigation on discontinuation of oral anticoagulation after paroxysmal atrial fibrillation catheter ablation in China","volume":"9","author":"Yu","year":"2020","journal-title":"Ann Palliat Med"},{"key":"2026070720300632200_euag104-B35","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1536\/ihj.18-517","article-title":"Adverse clinical events during long-term follow-up after catheter ablation of atrial fibrillation: comparison to a non-ablation patient group","volume":"60","author":"Arai","year":"2019","journal-title":"Int Heart J"},{"key":"2026070720300632200_euag104-B36","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e32516","article-title":"Real world risk of discontinuing oral anticoagulation after successful catheter ablation for atrial fibrillation","volume":"10","author":"Fei","year":"2024","journal-title":"Heliyon"},{"key":"2026070720300632200_euag104-B37","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.119.007612","article-title":"Outcomes and anticoagulation use after catheter ablation for atrial fibrillation","volume":"12","author":"Freeman","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2026070720300632200_euag104-B38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2459\/JCM.0000000000000311","article-title":"Long-term events following atrial fibrillation rate control or transcatheter ablation: a multicenter observational study","volume":"17","author":"Gallo","year":"2016","journal-title":"J Cardiovasc Med"},{"key":"2026070720300632200_euag104-B39","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijcard.2021.02.057","article-title":"Discontinuation of oral anticoagulation and risk of stroke and death after ablation for typical atrial flutter: a nation-wide Danish cohort study","volume":"333","author":"Giehm-Reese","year":"2021","journal-title":"Int J Cardiol"},{"key":"2026070720300632200_euag104-B40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jjcc.2020.09.001","article-title":"Long-term efficacy and safety of anticoagulation after atrial \ufb01brillation ablation: data from the JACRE registry","volume":"77","author":"Inoue","year":"2021","journal-title":"J Cardiol"},{"key":"2026070720300632200_euag104-B41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18103\/mra.v10i6.2837","article-title":"Cardiovascular outcomes associated with oral anticoagulants, antiplatelets and no-treatment after atrial fibrillation ablation: a nationwide cohort study","volume":"10","author":"Karasoy","year":"2022","journal-title":"Med Res Arch"},{"key":"2026070720300632200_euag104-B42","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jjcc.2025.04.004","article-title":"Association between oral anticoagulants continuation on thromboembolism and bleeding events in patients with CHADS2 score 0\u20132 points after catheter ablation for persistent atrial fibrillation","volume":"86","author":"Nakano","year":"2025","journal-title":"J Cardiol"},{"key":"2026070720300632200_euag104-B43","doi-asserted-by":"crossref","DOI":"10.1111\/anec.70067","article-title":"Assessment of long-term use versus discontinuation of direct oral anticoagulant after catheter ablation for atrial fibrillation-RYOUMA registry subanalysis","volume":"30","author":"Oda","year":"2025","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"2026070720300632200_euag104-B44","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/jce.14864","article-title":"Continuous rhythm monitoring-guided anticoagulation after atrial fibrillation ablation","volume":"32","author":"Pothineni","year":"2021","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026070720300632200_euag104-B45","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/jce.12387","article-title":"Risk of stroke or transient ischemic attack after atrial fibrillation ablation with oral anticoagulant use guided by ECG monitoring and pulse assessment","volume":"25","author":"Riley","year":"2014","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026070720300632200_euag104-B46","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00392-023-02319-9","article-title":"Prevention of cerebral thromboembolism by oral anticoagulation with dabigatran after pulmonary vein isolation for atrial fibrillation: the ODIn-AF trial","volume":"113","author":"Schrickel","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"2026070720300632200_euag104-B47","doi-asserted-by":"crossref","DOI":"10.1111\/anec.70067","article-title":"Assessment of long-term use versus discontinuation of direct oral anticoagulant after catheter ablation for atrial fibrillation\u2014RYOUMA registry subanalysis","volume":"30","author":"Oda","year":"2025","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"2026070720300632200_euag104-B48","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1161\/CIRCEP.111.963231","article-title":"Very low risk of thromboembolic events in patients undergoing successful catheter ablation of atrial fibrillation with a CHADS2 score\u2264 3: a long-term outcome study","volume":"4","author":"Saad","year":"2011","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2026070720300632200_euag104-B49","article-title":"It can be safe to discontinue oral anticoagulants after successful atrial fibrillation ablation: a systematic review and meta-analysis of cohort studies","volume":"102","author":"Wang","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"2026070720300632200_euag104-B50","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1161\/STROKEAHA.119.026890","article-title":"Atrial fibrillation ablation and reduction of stroke events","volume":"50","author":"Barra","year":"2019","journal-title":"Stroke"},{"key":"2026070720300632200_euag104-B51","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.3390\/jcm14082648","article-title":"Atrial fibrillation ablation: impact on burden and cardiovascular outcomes","volume":"14","author":"AlTurki","year":"2025","journal-title":"J Clin Med"},{"key":"2026070720300632200_euag104-B52","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5853\/jos.2016.00234","article-title":"The mechanism of and preventive therapy for stroke in patients with atrial fibrillation","volume":"18","author":"Kim","year":"2016","journal-title":"J Stroke"},{"key":"2026070720300632200_euag104-B53","doi-asserted-by":"crossref","DOI":"10.1002\/joa3.13194","article-title":"Novel anticoagulation therapy using apple watch after catheter ablation for atrial fibrillation-up to AF trial: design and rationale","volume":"41","author":"Sunaga","year":"2025","journal-title":"J Arrhythm"},{"key":"2026070720300632200_euag104-B54","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euae043","article-title":"2024 European Heart Rhythm Association\/Heart Rhythm Society\/Asia Pacific Heart Rhythm Society\/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation","volume":"26","author":"Tzeis","year":"2024","journal-title":"Europace"},{"key":"2026070720300632200_euag104-B55","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euae134","article-title":"State-of-the-art pulsed field ablation for cardiac arrhythmias: ongoing evolution and future perspective","volume":"26","author":"Chun","year":"2024","journal-title":"Europace"},{"key":"2026070720300632200_euag104-B56","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euaf250","article-title":"Adherence to oral thromboprophylaxis in atrial fibrillation: an overview for clinicians","volume":"27","author":"Potpara","year":"2025","journal-title":"Europace"},{"key":"2026070720300632200_euag104-B57","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euae280","article-title":"Refining the CHA2DS2VASc risk stratification scheme: shall we drop the sex category criterion?","volume":"26","author":"Yoshimura","year":"2024","journal-title":"Europace"},{"key":"2026070720300632200_euag104-B58","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euae298","article-title":"Spotlight on the 2024 ESC\/EACTS management of atrial fibrillation guidelines: 10 novel key aspects","volume":"26","author":"Rienstra","year":"2024","journal-title":"Europace"}],"container-title":["Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/28\/7\/euag104\/68706082\/euag104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/28\/7\/euag104\/68706082\/euag104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:30:17Z","timestamp":1783470617000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/doi\/10.1093\/europace\/euag104\/8725960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,3]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euag104","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7]]},"article-number":"euag104"}}